[{"id":"f52ea7ba-bfbd-4917-b198-17afffc30288","acronym":"","url":"https://clinicaltrials.gov/study/NCT05553834","created_at":"2022-09-23T17:07:20.162Z","updated_at":"2024-07-02T16:35:01.068Z","phase":"Phase 2","brief_title":"PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung","source_id_and_acronym":"NCT05553834","lead_sponsor":"Duke University","biomarkers":" EGFR • BRAF • MET • ROS1 • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • BRAF • MET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • Praluent (alirocumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/16/2023","start_date":" 05/16/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2029","study_completion_date":" 01/01/2029","last_update_posted":"2024-05-24"}]